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Abstract
Approximately 80% of breast cancers (BC) are estrogen 
receptor (ER)-positive and thus endocrine therapy (ET) 
should be considered complementary to surgery in the 
majority of patients. The advantages of oophorectomy, 
adrenalectomy and hypophysectomy in women with 
advanced BC have been demonstrated many years 
ago, and currently ET consist of (1) ovarian function 
suppression (OFS), usually obtained using gonadotropin-
releasing hormone agonists (GnRHa); (2) selective 
estrogen receptor modulators or down-regulators 
(SERMs or SERDs); and (3) aromatase inhibitors (AIs), 
or a combination of two or more drugs. For patients 
aged less than 50 years and ER+ BC, there is no 
conclusive evidence that the combination of OFS and 
SERMs (i.e. , tamoxifen) or chemotherapy is superior 
to OFS alone. Tamoxifen users exhibit a reduced risk 
of BC, both invasive and in situ , especially during the 
first 5 years of therapy, and extending the treatment 
to 10 years further reduced the risk of recurrences. 
SERDs (i.e. , fulvestrant) are especially useful in the 
neoadjuvant treatment of advanced BC, alone or in 
combination with either cytotoxic agents or AIs. There 
are two types of AIs: type Ⅰ are permanent steroidal 
inhibitors of aromatase, while type Ⅱ are reversible 
nonsteroidal inhibitors. Several studies demonstrated the 
superiority of the third-generation AIs (i.e. , anastrozole 
and letrozole) compared with tamoxifen, and adjuvant 
therapy with AIs reduces the recurrence risk especially 
in patients with advanced BC. Unfortunately, some 
cancers are or became ET-resistant, and thus other 
drugs have been suggested in combination with SERMs 
or AIs, including cyclin-dependent kinase 4/6 inhibitors 
(palbociclib) and mammalian target of rapamycin 
(mTOR) inhibitors, such as everolimus. Further studies 
are required to confirm their real usefulness. 
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Core tip: In women with breast cancer (BC), the two 
major endocrine therapies (ET) available are directed 
at blocking estrogen receptors (ERs) on cancer cells 
(selective estrogen receptor modulators), or against 
the key enzyme in the biosynthesis of estrogens 
(aromatase inhibitors). The new knowledge about 
molecular mechanisms regulating tumor progression, 
suggested the existence of a strict relationship between 
ERs, intracellular signaling pathways, and other growth 
factors receptor, which justify the escape of a portion 
of patients from the inhibitory effects of ET. To restore 
endocrine sensitivity of BC cells, molecular-target 
therapies are giving encouraging results, but further 
studies are required to confirm their real usefulness.  
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INTRODUCTION
Breast cancer (BC) is the most common female 
cancer worldwide, and the second cause of cancer 
death in women[1]. In the United States, the expected 
number of new BC cases in 2015 is approximately 
231800, accounting for 29% of all cancers, with an 
annual change based on incidence of +0.3%[2]. In the 
European Union, BC seems to have a more favorable 
trend, with a 10.2% fall from 2009[3]. 
Estrogen receptors (ERs) are nuclear proteins 
regulating the expression of specific genes, and 
approximately 80% of BCs are estrogen receptor (ER)-
positive, of which 65% are also progesterone receptor 
(PR)-positive[4]. Thus, endocrine therapy (ET) should be 
considered complementary to surgery in the majority 
of patients, inducing tumor remission and providing 
consistent clinical benefit. ET has represented the 
standard adjuvant treatment for ER+ tumors since 
the 1970s, although the advantages of oophorectomy, 
adrenalectomy, and hypophysectomy in women 
with advanced BC had already been demonstrated 
many years before[5]. ET for BC currently consist of 
(1) ovarian function suppression (OFS); (2) selective 
estrogen receptor modulators (SERMs); (3) selective 
estrogen receptor down-regulators (SERDs); and (4) 
aromatase inhibitors (AIs), or a combination of two or 
more drugs. The two major strategies are directed at 
blocking ERs of cancer cells (SERMs) or against the key 
enzyme in the biosynthesis of estrogens (AIs). 
OVARIAN FUNCTION SUPPRESSION 
For decades, in premenopausal women with operable 
BC in whom ovaries are the main source of estrogen and 
progesterone, surgical oophorectomy has represented 
an effective adjuvant therapy. Ovary irradiation was 
rarely performed for this purpose. Recently, it has been 
shown that the timing of oophorectomy (i.e., luteal 
phase of the menstrual cycle) does not affect disease-
free survival (DFS) and overall survival (OS) of patients 
with BC[6]. OFS can be also obtained using gonadotropin-
releasing hormone agonists (GnRHa), which are 
generally considered drugs with reversible actions. 
Although in patients with BC undergoing simultaneously 
GnRHa administration and chemotherapy (CT) ovarian 
function is rarely preserved, this treatment has largely 
replaced surgery[7,8]. 
A historic large overview of randomized trials testing 
the usefulness of ovarian ablation in patients with ER+ 
early BC, named EBCTCG (Early Breast Cancer Trialists’ 
Collaborative Group) study, demonstrated that OFS 
significantly increases survival in women aged below 
50 years and that these benefits are independent of 
axillary nodal status, compared to untreated patients[9]. 
The advantages of adding a GnRHa to SERMS or CT 
in terms of reduced recurrence and deaths rate was 
confirmed in other studies[10,11]. More recently, it has 
been shown that women who underwent adjuvant 
GnRHa monotherapy or standard CT regimen had 
similar DFS and OS, while a combination of GnRHa 
plus CT or SERMs significantly improved DFS and OS in 
comparison to CT alone[12]. Further studies suggested 
that, in women with ER+ early BC, adjuvant treatment 
with OFS plus SERMs (tamoxifen) does not lead to 
any advantage, while the combination of OFS and 
AIs (exemestane) significantly reduces recurrences 
compared to the other regimen[13,14]. 
In premenopausal women previously treated with 
SERMs (tamoxifen), extended therapy with GnRHa and 
an AI may lead to substantial adverse effects[15]. In 
conclusion, for patients aged less than 50 years, there 
is no conclusive evidence that the combination of OFS 
and SERMs or CT is superior to OFS alone[16]. 
SELECTIVE ER MODULATORS AND 
DOWN-REGULATORS
Tamoxifen (TAM) is the drug most extensively used 
when an ET is required, both in pre- and postme-
nopausal women, and is still considered the SERM 
of choice[7]. TAM (Figure 1A) was initially studied 
as anti-fertility drug, demonstrating soon favorable 
effects in patients with ER+ BC, as well as on bone 
tissue and cardiovascular system[17]. TAM acts as a 
partial nonsteroidal agonist in some tissues, such as 
liver, uterus and bone, but is a competitive receptor 
inhibitor in the breast and brain[18]. In these tissues, 
TAM selectively blocks signaling at the level of ERs, 
also inhibiting the proliferation of ductal cells[19]. TAM 
is hydroxylated by the cytochrome P450 enzyme 
system into 4-hydroxy tamoxifen (4HT), and further 
metabolized in the liver, thanks to a CYP2D6-mediated 
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oxidation, to endoxifen (4-hydroxy-N-desmethyl-
tamoxifen)[20]. Endoxifen and 4HT are the main active 
metabolites of TAM, exhibit similar ability in binding 
to ERs, and are more potent than TAM in suppressing 
estrogen-dependent cancer cells[7]. The relationship 
between CYP2D6, endoxifen or 4HT serum levels and 
the response to TAM therapy has long been studied, but 
the hypothesized role of CYP2D6 genotype as prognostic 
factor affecting recurrence in patients with BC was 
not confirmed[21,22]. However, CYP2D6 inhibitors, such 
as antipsychotic drugs, selective serotonin reuptake 
inhibitors (SSRIs), and some cardiac medications have 
the potential to affect response to SERM therapy[23,24]. 
TAM significantly benefits only women with ER+ 
BC, and ASCO (American Society of Clinical Oncology) 
guideline recommendations consider a cut-off of 1% 
for immunohistochemical testing of ERs in BC cells[25]. 
A number of studies and meta-analyses confirm its 
usefulness. According to the 2011 EBCTCG study, the 
reduction in mortality, expressed as reduction in annual 
odds of death, is approximately 20% after 5-years of 
TAM adjuvant therapy, and the 15-year recurrence rate 
ranges from 4.6% to 17.4%, according to age[16,26]. 
The long-term mortality among TAM users was 23.9% 
compared with 33.1% of the control group, with limited 
age-related side effects, such as increased risk of 
thromboembolic disease (> 55 years) and endometrial 
cancer (> 45 years)[26,27]. Extending the treatment to 
10 years, the risk of recurrence and overall mortality 
are further slightly reduced, and thus the 2014 ASCO 
guidelines recommend the use of TAM for up to 10 
years in pre- or perimenopausal women[28,29]. 
With the aim of limiting the incidence of adverse 
effects of TAM, eventually improving its effectiveness, 
other SERMs have been proposed, such as toremifene 
and raloxifene, both approved by the US Food and 
Drugs Administration (FDA). Toremifene (Figure 
1B) is similar to TAM in clinical activity, efficacy and 
tolerability, and is cross-resistant to TAM. It causes 
less vascular and endometrial adverse effects than 
TAM, but has less favorable actions on bone and 
lipids levels[30]. Also in patients with metastatic 
BC, the results of TAM and toremifene therapy did 
not differ significantly, and the latter represents a 
reliable alternative to TAM in menopausal women[31]. 
Raloxifene (Figure 1C) is another nonsteroidal SERM 
causing less toxicity compared to TAM, especially used 
for the prevention of osteoporosis in postmenopausal 
women[32]. However, as preventive therapy, raloxifene 
has been shown to be less effective than TAM, because 
it reduces the risk of cancer by 36% compared to 50% 
of the group treated with TAM[33]. 
In conclusion, SERMs users exhibit a reduced risk 
of BC, both invasive and in situ, especially during the 
first 5 years of therapy, ranging from 53% to 79% 
according to age and menopausal status[34].
Selective estrogen receptor down-regulators have 
different pharmacologic characteristics, biochemi-
cal structure, and molecular activity with respect of 
SERM, causing down-regulation and degradation 
of ERs, and inhibiting proliferation of estrogen-
dependent BC cells[35]. SERDs are pure ER antagonist, 
blocks ERs activity and accelerate their degradation, 
thus exhibiting exclusively anti-estrogen effects[36]. 
Fulvestrant, the only SERD approved by FDA to treat 
patients with BC, has 100-fold the affinity of TAM for 
ER, in lack of adverse effect on endometrial ERs[37,38]. 
It is useful especially in patients with advancer BC and 
as second-line therapy in TAM-resistant tumors[36]. 
Fulvestrant sensitizes ER-negative BC to chemotherapy, 
showing a synergistic action with various cytotoxic 
agents, such as docetaxel[39,40]. In the treatment of 
patients with metastatic ER+ BC, the combination 
of fulvestrant plus an AI (anastrozole) was superior 
to anastrozole alone, and fulvestrant as single-drug 
therapy represents a reasonable alternative to AIs[41,42]. 
In the neoadjuvant setting, the use of fulvestrant is 
controversial, because of the slow response rate and 
possible non-response. In a phase Ⅱ randomized 
study, tumor response rates were 20.6% and 22.9%, 
according to the dosage of the drug[43]. 
AROMATASE INhIbITORS
The human CYP19 single-copy gene, located on chro-
mosome 15q21.2, encodes the microsomal enzyme 
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Figure 1  Chemical structures of the main selective estrogen receptor modulators.
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leading to the need of increasing the dosage of the 
drug, and requires corticosteroids supplementation. 
Due to these side effects, aminoglutethimide has been 
replaced by better-tolerated and more effective AIs[7]. 
Exemestane (Figure 3B) is a potent irreversible 
steroidal AI that acts as a false substrate for aromatase 
and suppresses selectively estrogens at any site[50]. 
In some studies, exemestane plus OFS reduced the 
risk of recurrences in premenopausal women with 
ER+ early BC, while TAM plus OFS did not provided 
benefit[51]. In a group of postmenopausal patients 
at slightly increased risk of cancer according to the 
Gail model who underwent exemestane therapy, the 
annual incidence of BC was 0.33% compared to 0.77% 
of control group[52]. 
Anastrozole and letrozole (Figure 4) are two non-
stedroidal third-generation AIs with similar potency 
and characteristics. Because their block of ERs is 
reversible, a continuous drug administration is required. 
An old comparison between anastrozole and letrozole 
as second-line therapy in advanced BC, reported an 
overall response rate of 12% vs 19%, respectively[53]. 
In postmenopausal women with advanced BC, letrozole 
was more effective than fadrazole, a second-generation 
type Ⅱ nonsteroidal AI with reversible action[54]. The 
more recent ACOSOG (American College of Surgeons 
Oncology Group) study compared exemestane, 
anastrozole, and letrozole as neoadjuvant therapy 
of women with advanced BC, and reported that the 
clinical response rate was 62.9%, 69.1%, and 74.8%, 
respectively[55]. Several meta-analysis underline the 
aromatase [cytochrome P450 19 (CYP19)], which 
catalyzes the conversion of androgens, such as tes-
tosterone and androstenedione, to estrogens, such as 
17-β-estradiol and estrone[44] (Figure 2). 
Aromatase activity is expressed especially in the 
ovary (premenopausal women), testis, placenta, brain, 
bone and adipose tissue (postmenopausal women)[45]. 
AIs block aromatase enzyme activity, safely reducing 
circulating estrogen levels only in postmenopausal 
patients. AIs are ineffective in premenopausal women 
with functionally active ovary in whom they increase 
gonadotropin secretion, and therefore estrogen 
production[46]. The combination of AIs and OFS, using 
a GnRHa to block the pituitary, is usually an effective 
strategy. According to the conclusions of the STAGE 
study, 70.4% of postmenopausal patients with early 
BC treated with an AI (anastrozole) plus GnRHa 
(goserelin) obtained complete or partial response 
to therapy, compared with 50.5% of the control 
group treated with anastrozole plus TAM[47]. Another 
study, did not found any difference in DFS between 
premenopausal women with ER+ early BC treated with 
TAM alone and those treated with anastrozole alone, 
who presented a slightly increased risk of death[48]. 
A correlation between elevated body mass index 
and reduced effect of AIs has been reported in some 
studies[49]. 
According to the chemical structure and mechanism 
of action, there are two types of AIs: type Ⅰ are 
permanent steroidal inhibitors of aromatase, while 
type Ⅱ are reversible nonsteroidal inhibitors (Table 1). 
Aminoglutethimide, initially used as anti-epileptic 
drug, is the oldest nonsteroidal AI (Figure 3A). 
It inhibits also cytochrome P450scc, blocking the 
conversion of cholesterol to pregnenolone, and 
thus decreases the production of several steroids, 
including cortisol[17]. The subsequent activation of 
the hypothalamic-pituitary-adrenal axis, causes 
hypersecretion of adrenocorticotropic hormone (ACTH) 
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superiority of the third-generation AI (but not first- and 
second-generation AIs) compared with TAM, confirming 
that adjuvant therapy with AIs reduces the recurrence 
risk in patients with advanced BC, but does not affect 
mortality rate[56,57].  
ENDOCRINE ThERAPY AND 
MOLECULAR-TARGET ThERAPY
The new knowledge about molecular mechanisms 
regulating tumor progression, suggested the existence 
of a strict relationship between ERs, intracellular 
signaling pathways, and other growth factors receptor, 
which justify the escape of a portion of patients from 
the inhibitory effects of ET[58]. To restore endocrine 
sensitivity of ER+ cancer cells, several other drugs have 
been studied, including cyclin-dependent kinase (CDK) 
4/6 inhibitors (palbociclib), epigenetic modulators that 
inhibit histone deacetylase (HDAC), and other signal 
pathway inhibitors[59]. Experimentally, combined HDAC 
inhibition and TAM reverse ET resistance, inducing 
apoptosis of TAM-resistant BC cells, and in women 
with advanced ER+ BC and disease progression or 
recurrence the progression-free survival (PFS) can 
be reduced adding palbociclib to letrozole[60,61]. The 
phosphoinositide 3-kinase (PI3K)/protein kinase 
B (AKT) pathway and the serine/threonine kinase 
mammalian target of rapamycin (mTOR) are part of 
a signaling network regulating several cell processes, 
including growth, proliferation and survival of cancer 
cells[62]. The addition of an mTOR inhibitor (everolimus) 
to examestane in patients with ER+ BC and advanced 
disease refractory to both SERMs and AIs, can improve 
the progression-free survival (PFS) compared to 
everolimus alone[52]. A recent meta-analysis showed 
that exemestane and everolimus in combination was 
more efficacious than fulvestrant alone in patients 
with relapsed BC previously treated with nonsteroidal 
AIs[63]. Unfortunately, in women with ER+ BC, the 
addition of an anti-vascular endothelial growth factor 
(bevacizumab) to fulvestrant or letrozole did not 
change the resistance of the tumor to ET, and failed to 
improve PFS or OS[64].
METASTATIC bREAST CANCER
As in part already reported above, anti-estrogen therapy 
plays a major role in the prolonged remission in women 
with metastatic and advanced ER+ BC. Several studies 
showed that the inhibition of the aromatase enzyme 
system with third-generation AIs, such as exemestane, 
anastrozole and letrozole, is associated with better 
survival compared to SERMs[56]. In terms of both PFS 
and OS, there are also advantages of treating patients 
with AIs compared to other ET, and letrozole seems to 
be the drug of choice[65,66]. The adverse effects observed 
using letrozole or anastrozole are similar than that 
observed with TAM, and the time-to-progression was 
better[67]. The combination anastrozole and fulvestrant 
in metastatic ER+ BC was superior to anastrozole 
alone[41]. 
All endocrine therapies, in particular AIs, synergize 
their effects with several molecular target drugs, such 
as everolimus and palbociclib[58,60]. It has also been 
shown that exemestane plus everolimus were more 
efficacious than everolimus alone and fulvestrant 
alone in women with advanced BC and progressive 
disease[52,63]. The GINECO (Groupe d’Investigateurs 
Nationaux pour les Etudes des Cancers de l’Ovaire) 
study showed that the short-term clinical benefit 
rates obtained with TAM plus everolimus vs TAM 
alone were 61% and 42%, respectively, and that the 
time to progression increased from 4.5 to 8.6 mo[68]. 
However, according to the conclusion of the BOLERO-2 
(Breast Cancer Trials of OraL EveROlimus-2) study, 
the decision of prescribing AIs and mTOR inhibitors 
in combination should be individualized, taking into 
account the characteristics of single patient and 
considering risks and benefits of the treatment[69]. 
Both CDK and HDAC inhibitors, such as palbociclib 
and etinostat, in combination with ET, can be useful 
in patients with advanced ER+ BC as third-line 
therapy[70].
ADVERSE EFFECTS
Unfortunately, both TAM and AIs use is associated 
with several adverse events (AEs) and distressing 
symptoms, such as hot flushes, weight gain, sex-
ual dysfunctions, decreased bone mineral density 
(BMD), osteoporosis and pathologic fractures, or mus-
culoskeletal symptoms, depending on the drug used 
and the duration of treatment. These effects may 
be severe enough to cause non-compliance due to 
cessation of use in a significant proportion of patients. 
Most of the AEs is related to the estrogen deprivation[7]. 
According to a systematic review, TAM was associated 
with more serious AEs in comparison with AIs, while 
exemestane caused more frequently musculoskeletal 
symptoms and hot flushes, but in some trials no 
Table 1  Main characteristics of type Ⅰ and Ⅱ aromatase inhibitors
Type Chemical structure Action First generation Second generation Third generation
   Ⅰ Steroidal Permanent Testolactone Formestane Examestane
   Ⅱ Nonsteroidal Reversible Aminoglutethimide Fadrozole Anastrozole
Letrozole
Lumachi F et al . Medical treatment of ER+ breast cancer
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differences in AEs between SERMs and AIs was 
found[67]. Another meta-analysis showed that patients 
treated with AIs had increased risk of gastrointestinal 
symptoms, such as nausea, vomiting and diarrhea, 
while the incidence of thromboembolic events and 
vaginal bleeding were decreased compared to other 
ETs[66]. In several studies, AIs use was associated 
with a higher risk of arthralgia and decreased BMD 
compared to TAM, and the incidence of discontinuation 
ranges from approximately 12% to 14%[16]. Effects on 
cognitive function related to the AIs use have also been 
reported, similar to the so-called “chemotherapy fog” 
observed following prolonged cancer CT[71]. However, 
toxicity is related to individual treatment compliance 
and depends on the way in which the patient describes 
and reports the symptoms, and they usually resolve 
with discontinuation of treatment[16]. Careful patient 
information is recommended before starting any 
treatment with ETs, especially in premenopausal 
women. 
CONCLUSION
In patients with BC and ER+ tumors, ET has several 
advantages, including prolonging DFS and OS, and 
reducing the risk of recurrence, both in patients with 
early BC and in those with advanced or relapsed 
disease. In premenopausal women, OFS and TAM has 
similar efficacy and there is no evidence that a regimen 
based on OFS, SERMs, or AIs in combination can be 
the strategy of choice[7,16]. In postmenopausal women, 
AIs are more effective than SERMs in reducing relapse 
of the disease, and extending the TAM administration 
for more than 5 year represents a useful strategy. In 
patients with advanced BC, molecular-target therapies 
are giving encouraging results, but further studies are 
required to confirm their real usefulness and a careful 
analysis of cost-benefits is also required. 
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